Andrew W. Lo

Faculty

Andrew W. Lo

About

Andrew W. Lo is the Charles E. and Susan T. Harris Professor, a Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management.

His current research spans five areas: evolutionary models of investor behavior and adaptive markets, systemic risk and financial regulation, quantitative models of financial markets, financial applications of machine-learning techniques and secure multi-party computation, and healthcare finance.  Recent projects include: deriving risk aversion, loss aversion, probability matching, and other behaviors as emergent properties of evolution in stochastic environments; constructing new measures of systemic risk and comparing them across time and systemic events; applying spectral analysis to investment strategies to decompose returns into fundamental frequencies; and developing new statistical tools for predicting clinical trial outcomes, incorporating patient preferences into the drug approval process, and accelerating biomedical innovation via novel financing structures.

Lo has published extensively in academic journals (see http://alo.mit.edu) and his most recent book is Adaptive Markets: Financial Evolution at the Speed of Thought.  His awards include Batterymarch, Guggenheim, and Sloan Fellowships; the Paul A. Samuelson Award; the Eugene Fama Prize; the IAFE-SunGard Financial Engineer of the Year; the Global Association of Risk Professionals Risk Manager of the Year; the Harry M. Markowitz Award; the Managed Futures Pinnacle Achievement Award; one of TIME’s “100 most influential people in the world”; and awards for teaching excellence from both Wharton and MIT. His book Adaptive Markets has also received a number of awards, listed here. He is a Fellow of Academia Sinica; the American Academy of Arts and Sciences; the Econometric Society; and the Society of Financial Econometrics.

Lo is also a principal investigator at the MIT Computer Science and Artificial Intelligence Laboratory, an affiliated faculty member of the MIT Department of Electrical Engineering and Computer Science, an external faculty member of the Santa Fe Institute, and a research associate of the National Bureau of Economic Research. He is a member of the New York Federal Reserve Board’s Financial Advisory Roundtable, FINRA’s Economic Advisory Committee, the National Academy of Sciences Board on Mathematical Sciences and Their Applications, Beth Israel Deaconess Medical Center’s Board of Overseers, and the boards of Roivant Sciences and the Whitehead Institute for Biomedical Research.

Lo holds a BA in economics from Yale University and an AM and PhD in economics from Harvard University.

Honors

Lo wins Jamieson Prize

Pinnacle Achievement Award Given to Lo

GARP honors Lo as Risk Manager of the Year

Lo’s book wins PROSE Award

Markowitz Award given to Lo

Publications

"Fair and Responsible Drug Pricing: A Case Study of Radius Health and Abaloparatide."

Xu, Qingyang, and Andrew W. Lo. Journal of Investment Management. Forthcoming.

Healthcare Finance.

Lo, Andrew W. and Shomesh Chaudhuri. Forthcoming.

In Pursuit of the Perfect Portfolio.

Foerster, Stephen R., and Andrew W. Lo. Forthcoming.

"Is It Real or Is It Randomized?: A Financial Turing Test."

Hasanhodzic, Jasmina, Andrew W. Lo, and Emanuele Viola. Journal of Portfolio Management. Forthcoming.

"Macroeconomic Models for Monetary Policy: A Critical Review from a Finance Perspective."

Dou, Winston, Andrew W. Lo, Ameya Muley and Harald Uhlig. Annual Review of Financial Economics. Forthcoming. SSRN.

"Measuring Risk Preferences and Asset-Allocation Decisions: A Global Survey Analysis."

Lo, Andrew W., Alexander Remorov, and Zied Ben Chaouch. Journal of Investment Management. Forthcoming. SSRN Preprint.

Load More

Recent Insights

Ideas Made to Matter

3 policy proposals to bolster the post-lockdown economy

Financial experts call for more aid to small businesses, more liquidity for banks, penalty-free access to retirement accounts — and a safe return to work.

Read Article
Press

New statistical approach to COVID-19 clinical trials aims to accelerate drug approval process and attract more funding

The studies describe new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines.

Read Article
Load More

Media Highlights